Houston, we have a problem. Oh, wait. I’m not talking about Stanislaw Burzynski this time. But we do still have a problem, and it’s a problem that resembles the Burzynski problem I recently discussed. Specifically, it’s a problem of unethical clinical trials somehow winning approval from institutional review boards (IRBs). In academia, IRBs are basically […]
